Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

PhytoMedical and Medicilon Seek China Partner for Cancer Drug

publication date: Apr 15, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
PhytoMedical Technologies, Inc. of Princeton, NJ, has signed a letter of intent with Shanghai Medicilon, a preclinical CRO. Under the terms of the proposed agreement, Medicilon will seek to find a China partner for PhytoMedical’s pre-clinical cancer compound. The price for the China rights to the drug will be payment for the compound’s pre-clinical development, which will be conducted by Medicilon. PhytoMedical and the partner will each be responsible for submitting the IND package to their respective agencies. More details...

Stock Symbol: (OTCBB: PYTO)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners